Overview

Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This pilot study compares two photosensitizers, hexylaminolaevulinate (HAL) and methylaminolaevulinate (MAL), in treatment of actinic keratoses. Study is conducted using randomized split-face design. Efficacy is assessed clinically, and histologically at 3 and 12 months. Pain during and after treatments and adverse reactions at one week are recorded.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Joint Authority for Päijät-Häme Social and Health Care
Collaborator:
Helsinki University Central Hospital
Treatments:
Aminolevulinic Acid
Methyl 5-aminolevulinate